NBS SEEKING ALPHA ARTICLE //NeoStem: The Best Upside In An

New Post Public Reply Private Reply Replies (0) Message Board

Oct 9, 2012 at 9:19 AM

[b]NBS >> SEEKING ALPHA ARTICLE //NeoStem: The Best Upside In An Innovating Space[/b]
October 7, 2012
by: Henry Kawabe
| about: NBS, includes: BAX, CUR, OSIR, STEM
Disclosure: I am long NBS. (More...)

There is one change in the medical arena that investors are going to have to embrace, or at least accept: cell
therapy. In 2012, some of the best performing stocks in biotechnology have been in cell therapy. Already, we have
crossed a number of barriers. We've seen the first approved product with a cell therapy as a main component: Osiris
Therapeutics' (OSIR) Prochymal. Shares of Neuralstem (CUR) have nearly doubled in the last month alone as its
cell therapy showed a benefit of motor function in paralysis, a benefit never before reached. StemCells (STEM) has
also been a big-time performer following data that its cell therapy restored memory and enhanced synaptic function in
Alzheimer's disease. And if that's not enough, Baxter (BAX) recently reached endpoints never before conquered,
increasing exercise capacity and reducing angina due to chronic myocardial ischemia. The takeaway: It has been an
incredible year, and with such breakthrough data, it is only getting better.
In biotechnology, we've seen a number of novel therapeutics with crucial data as we inch closer to curing and
effectively treating life-threatening diseases. Cell therapy has been at the forefront of this movement - it has provided
proof of concept curing some of today's most deadly degenerative diseases - but is still in its early stages of
development.
With only one approved product that has a cell therapy as its main component, the potential for new treatments and
the outlook for those treatments is at an all-time high. The valuation for companies in this space is particularly
attractive, perhaps greater than in any other industry within biotechnology. The reason for attractive valuations is due
to skepticism among some who have yet to embrace the benefits of cell therapy. These people may believe that we'll
never see a large diversified product line of cell therapies, or that regulators will never accept the benefits of cell
therapy. However, this argument doesn't make sense, because countries around the globe are spending more on cell
therapies than at any point in our history. There is a significant cost benefit to cell therapies, not to mention
efficiency, that will replace inefficient therapeutics that are being used to treat degenerative diseases. For this reason,
we will see approvals in the cell therapy arena. We will see cheaper and more efficient therapies to treat diseases
that have limited or no current treatments, and this will occur because of clinical results, and over a period of several
years.
So how should investors play the growth of this space? Investors could invest in a company such as CUR or STEM.
But these companies are still early in the clinical process, and are more likely to benefit from the approvals of other
cell therapies; they will trade with far less upside than later-stage companies with similar valuations. You could invest
in the first approved cell therapy and OSIR. However, its product Prochymal is more of a "door opener" and not a
large revenue-producing product. The difficult aspect to finding a good investment is that there are a lot of cell therapy
companies with a lack of diversification-or only one significant product of growth-and we must assume that, despite
their promise, it may take a few years for cell therapies to gain full acceptance and reach full potential. So after
searching throughout the entire space, and reading 100s of reviews, business plans, and assessing market potential,
I feel confident that the best play in the space is NeoStem Inc. (NBS).
NeoStem
NeoStem is a $105 million market capitalization company with expertise and a presence that stretches far beyond
the norm of cell therapy and developmental-stage companies. The company operates in several segments, with a
diversified presence in the space, and has been a great investment in 2012, with an 81% return over the last six
months. The stock has returned a gain of more than 10% over the last month, but is now trading very close to its
support, therefore indicating short-term upside. Unlike most biotechnology companies of its size, NeoStem has

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dr. Liedtka's LIVE Model: Balance Life’s Priorities

Finding Balance in a Chaotic World Forget the market roller coaster for a second. Let's chat about something else that often feels like a roller coaster—life itself. Dr. Karl D. Liedtka's book, "Be Present, LIVE Fully," dives into that hot mess and offers a way to get a grip on your own sanity. This isn't just another self-help book filled with empty platitudes; it's...

Lab Glassware Market Set for Steady Growth by 2031

When you dive into the world of laboratory glassware, it might look like it's all pipettes and test tubes, but there's more bubbling under the surface. This market's got its eyes on a neat little climb from $7,630 million in 2026 to a forecasted $9,170 million by 2031. Ain't just speculation—this one's solid muscle growing at a comfortable 4.0% compound annual growth...

CDTL's E-Drive and EMB Shape Future of Automation

A Bumpy Ride Towards Future of Commercial Vehicles In the midst of a bustling Hannover, CDTL, that plucky contender in e-drive systems, is making noise at IAA Transportation 2026. Now, if there's one thing I've learned watching this circus we call the auto industry, it's that innovation rarely strolls in with a polite knock. It barges through the door, often leaving a...

GEEKOM A5 2027: Mini PC Built to Boost Your Game

GEEKOM Raises the Bar with A5 2027 Build Every once in a blue moon, a piece of tech pricks up my ears and this time it's the GEEKOM A5 2027 Edition. Released on September 7, 2026, this contraption's not just joining the ranks—it's looking to redefine them. It's geared for the real-world junkie who’s raking through browser tabs, dropping into video meetings, and making...

Lida Group Expands Global Modular Construction Services

Modular Construction's Expanding Footprint Behold Lida Group—a titan in the world of modular construction—taking ambitious strides into the global arena, reaching from the sand dunes of Saudi Arabia to the bustling corridors of the United Nations. If you haven't been paying attention, now's the time to get your head in the game. Their expansion isn't just about...

Tech Breakthroughs in Cancer and Space Energy Aired

Science and Technology at the Forefront Saturday nights usually have folks kicking back with some reality shows or maybe cheering on their favorite sports team. But this September 12, savvy viewers have a chance to dive deep into the guts of cutting-edge science and tech on Bloomberg Television. We're talking about 'Advancements with Ted Danson'—where science isn’t...

Cold Plasma Market Surges: $3.03 Billion by 2031

Cold Plasma's Rising Star in High-Tech Markets It's no secret that in the climb to technological dominance, industries are hunting for the next big play. Enter cold plasma. We're talking about a market anticipated to leap from USD 2.15 billion in 2026 to USD 3.03 billion by 2031. To those of us who've been grinding in the weeds of market trends, a 7.1% CAGR over half a...

Chef André Chiang Reimagines A Joy's Autumn Menu

The Culinary World of Chef André Chiang There's a brand-new aroma wafting through Taiwan's dining scene, and it's got Chef André Chiang's signature all over it. Partnering with A Joy, a high-end buffet restaurant, this all-star chef is giving us something worth the chatter: an autumn menu that's as much about memories as it is about taste. We're looking at flavors that...

Six Flags Offers Flexible Payment Plan with Flex Pay

New Payment Option Brings Flexibility Seems like Six Flags isn't just about roller coasters anymore—now they're playing the long game with wallet-friendly options. Flex Pay by Upgrade is the latest spin on season pass financing, letting guests divvy up payments and kickstart their amusement park fun right away. This move could be a game-changer for folks looking to lock...

Sony Expands Versatile Wireless Headphone Lineup: 2026

Renewed Focus on Sound: Sony's Latest Headphones Sony's dipping into the headphone market this time with a splash of style and sound signature updates. We've got the WH-1000XM4C, a next-gen version of the top-dog noise-cancelling cans, that are gonna catch the eye of every audiophile and traveler out there. WH-1000XM4C: The Flagship gets a Lift What they're offering is...